Parexel, a provider of services from clinical through commercialization, has signed a new master service agreement (MSA) with Pfizer Inc. This continues the companies decade-long strategic partnership. The agreement is for a three-year term with an option to extend for an additional two years. The strategic focus of the new agreement is focused on driving cycle times for Pfizer’s development efforts. Parexel will provide clinical development services via full-service, hybrid and functional se...